The anti-MUC16 antibody Oregovomab compared to placebo showed no survival benefit for patients with recurrent ovarian cancer after first-line therapy in the whole study group but a significantly greater disease-free survival in a subpopulation more amenable to immunotherapy in a randomized, double-blind study [24]. Here, MUC16 is linked to ovarian carcinoma.